ABOUT CAIRN

Cairn Biosciences discovers new medicines by mapping multiscale cell dynamics. Our proprietary COMPASS discovery platform unlocks exclusive routes to novel targets and drugs by navigating uncharted, complex and dynamic disease biology.

Using COMPASS, our diverse, multidisciplinary team of experts in drug discovery, disease biology, engineering and computation is pioneering a new drug discovery paradigm that utilizes our innovative simulations of living biology to deliver better therapeutics.

We are initially orienting COMPASS to the exciting challenge of discovering new drugs that overcome acquired resistance to targeted cancer therapies.

MEET THE TEAM

Team

Mary Ludlam PhD

Founder & CEO

Established biopharma leader & serial drug discovery innovator.
Visionary pioneer of diverse novel technologies including synthetic & cell biology; high-throughput microscopy; preclinical in vivo imaging; microfluidics; solid state femtosecond lasers & computational analysis.
Critical role in several blockbuster oncology programs including venetoclax & polatuzumab

Susana Abreu Ribeiro PhD

Director Discovery Data;
Paris Site Head

Multidisciplinary expert & leader of cross-continental biology & data science teams in San Francisco & Paris.
Fearless cell biologist & tool builder experienced in AI/ML, CRISPR & high-content screening & synthetic biology.
Ron Vale (HHMI, UCSF) & Bill Earnshaw FRS (Wellcome Center, U. Edinburgh) lab alumna with substantial expertise in cellular dynamics & oncology.

Payman Amiri PhD

CSO

Skilled preclinical oncology marshal with deep expertise in MAPK mechanistic biology and proven achievements in efforts to drug KRAS mutant cancers

Highly experienced cellular pharmacologist with extensive background cancer target identification, IND filings and patient stratification for clinical trials

Key contributions in drug discovery and development for multiple late stage clinical and approved therapeutic programs.